MYC and breast carcinoma: To investigate whether c-Myc and E2F1 downregulation was involved in combination of FB23 and ibrutinib-suppressed breast cancer progression, we explored the effects of c-Myc and E2F1 overexpression (OE), both individually and in co-overexpression.